In a highly anticipated announcement, Pfizer said on Monday a Phase 2/3 trial showed its COVID-19 vaccine was safe and generated a "robust" antibody response in children ages 5 to 11.
Business daily
Merkez mahallesi mutlu han sokak no:17/2 Bartın/Sakarya
info@businessdaily.com.tr